Summary
USV will add Wellbeing Nutritions portfolio while planning for the GLP-1 therapy segment as semaglutide patents expire
Source: BusinessLine
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
